Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Brooks Laboratories Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Day's Range
Low
₹60.60
High
₹61.60
Price Summary
| Previous Close | ₹61.00 |
|---|---|
| Day's Range | ₹60.60 - ₹61.60 |
| Open | ₹61.60 |
| 52 Week Range | ₹36.30 - ₹164.02 |
| Volume | 3,030 |
| Market Cap | ₹0.00 |
| Previous Close | ₹60.02 |
|---|---|
| Day's Range | ₹60.02 - ₹62.95 |
| Open | ₹62.95 |
| 52 Week Range | ₹36.90 - ₹165.95 |
| Volume | 1,023 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 1.85 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 7.54 |
| TTM EPS (₹) | 8.35 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 1.51 |
| PAT Margin (%) | -12.07 |
| Face Value (₹) | 10.00 |
| ROCE(%) | -10.03 |
| Trade Value ( ₹ in Lacs) | 0.61 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 7.54 |
| TTM EPS (₹) | 8.35 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 1.51 |
| PAT Margin (%) | -12.07 |
| Face Value (₹) | 10.00 |
| ROCE(%) | -10.03 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 825.57 | 233.17 |
| Expenses | N/A | N/A |
| PBT | -97.92 | 15.47 |
| Operating profit | 0.0 | 0.0 |
| Net profit | -99.67 | 13.72 |
About Brooks Laboratories Ltd.
| Founded | 2002 |
|---|---|
| NSE Symbol | BROOKS |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,67,870.32 | 1,956.60 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,20,945.52 | 8,260.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,90,906.63 | 5,054.05 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,26,818.07 | 8,858.45 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,18,673.63 | 1,462.70 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,11,346.37 | 1,118.40 | 835.50 - 835.50 |
| Lupin Ltd. | 1,08,639.01 | 2,398.45 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,06,086.80 | 1,093.40 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,02,193.79 | 2,464.50 | 1,909.70 - 1,909.70 |
| Lenskart Solutions Ltd. | 98,733.25 | 568.95 | 0.00 - 0.00 |
No Records Found
Latest News
Jun
20
2026
Posted on Jun 20th 2026
Brooks Laboratories informs about partial sale of equity shares
Brooks Laboratories has informed that the Company at its board meeting held today, 19th June 2026 has approved sale of 51,220 equity shares held by the Company in Brooks Steriscience to Steriscience Specialities.
The above information is a part of company’s filings submitted to BSE.
Read More
Aug
4
2026
Posted on Aug 4th 2026
Blue Jet Healthcare - Quaterly Results
The sales for the June 2026 quarter moved down to Rs. 2931.13 millions as compared to Rs. 3547.58 millions during the year-ago period.The Company's Net profit for the June 2026 quarter have declined marginally to Rs. 782.64 millions as against Rs. 911.70 millions reported during the corresponding quarter ended.Operating Profit reported a sharp decline to 1133.12 millions from 1292.48 millions in the corresponding previous quarter.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 2931.13 | 3547.58 | -17.38 | 2931.13 | 3547.58 | -17.38 | 9473.21 | 10299.85 | -8.03 |
| Other Income | 152.37 | 82.54 | 84.60 | 152.37 | 82.54 | 84.60 | 686.54 | 462.56 | 48.42 |
| PBIDT | 1133.12 | 1292.48 | -12.33 | 1133.12 | 1292.48 | -12.33 | 3627.53 | 4239.86 | -14.44 |
| Interest | 6.60 | 6.90 | -4.35 | 6.60 | 6.90 | -4.35 | 62.39 | 0.98 | 6266.33 |
| PBDT | 1126.52 | 1285.58 | -12.37 | 1126.52 | 1285.58 | -12.37 | 3565.14 | 4238.88 | -15.89 |
| Depreciation | 67.06 | 56.98 | 17.69 | 67.06 | 56.98 | 17.69 | 240.02 | 177.89 | 34.93 |
| PBT | 1059.46 | 1228.60 | -13.77 | 1059.46 | 1228.60 | -13.77 | 3325.12 | 4060.99 | -18.12 |
| TAX | 276.82 | 316.90 | -12.65 | 276.82 | 316.90 | -12.65 | 846.96 | 1008.96 | -16.06 |
| Deferred Tax | 11.82 | 18.90 | -37.46 | 11.82 | 18.90 | -37.46 | 34.06 | 41.21 | -17.35 |
| PAT | 782.64 | 911.70 | -14.16 | 782.64 | 911.70 | -14.16 | 2478.16 | 3052.03 | -18.80 |
| Equity | 346.93 | 346.93 | 0.00 | 346.93 | 346.93 | 0.00 | 346.93 | 346.93 | 0.00 |
| PBIDTM(%) | 38.66 | 36.43 | 6.11 | 38.66 | 36.43 | 6.11 | 38.29 | 41.16 | -6.98 |
Read More
Aug
4
2026
Posted on Aug 4th 2026
Glaxosmithkline Phar - Quaterly Results
The company witnessed a 14.86% growth in the revenue at Rs. 9244.20 millions for the quarter ended June 2026 as compared to Rs. 8048.30 millions during the year-ago period.Profit saw a slight increase of 23.76%to Rs. 2533.30 millions from Rs. 2047.00 millions.Operating profit surged to 3547.90 millions from the corresponding previous quarter of 2945.10 millions.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 9244.20 | 8048.30 | 14.86 | 9244.20 | 8048.30 | 14.86 | 37902.00 | 37234.90 | 1.79 |
| Other Income | 616.30 | 437.60 | 40.84 | 616.30 | 437.60 | 40.84 | 1425.60 | 1425.60 | 0.00 |
| PBIDT | 3547.90 | 2945.10 | 20.47 | 3547.90 | 2945.10 | 20.47 | 14427.60 | 13118.50 | 9.98 |
| Interest | 9.70 | 4.20 | 130.95 | 9.70 | 4.20 | 130.95 | 27.30 | 13.10 | 108.40 |
| PBDT | 3538.20 | 2940.90 | 20.31 | 3538.20 | 2940.90 | 20.31 | 14426.70 | 13152.30 | 9.69 |
| Depreciation | 158.40 | 155.20 | 2.06 | 158.40 | 155.20 | 2.06 | 664.40 | 667.90 | -0.52 |
| PBT | 3379.80 | 2785.70 | 21.33 | 3379.80 | 2785.70 | 21.33 | 13762.30 | 12484.40 | 10.24 |
| TAX | 846.50 | 738.70 | 14.59 | 846.50 | 738.70 | 14.59 | 3644.10 | 3293.80 | 10.64 |
| Deferred Tax | 33.00 | 0.20 | 16400.00 | 33.00 | 0.20 | 16400.00 | 94.60 | 62.00 | 52.58 |
| PAT | 2533.30 | 2047.00 | 23.76 | 2533.30 | 2047.00 | 23.76 | 10118.20 | 9190.60 | 10.09 |
| Equity | 1694.10 | 1694.10 | 0.00 | 1694.10 | 1694.10 | 0.00 | 1694.10 | 1694.10 | 0.00 |
| PBIDTM(%) | 38.38 | 36.59 | 4.88 | 38.38 | 36.59 | 4.88 | 38.07 | 35.23 | 8.04 |
Read More
Aug
4
2026
Posted on Aug 4th 2026
Unjha Formulations - Quaterly Results
The sales for the June 2026 quarter moved down to Rs. 33.07 millions as compared to Rs. 36.34 millions during the year-ago period.Net profit of the cmpany stood at Rs. 1.57 millions for the quarter ended June 2026 a decline of -59.64% from Rs. 3.89 millions in the same quarter last year.Operating Profit reported a sharp decline to 1.95 millions from 4.20 millions in the corresponding previous quarter.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 33.07 | 36.34 | -9.00 | 33.07 | 36.34 | -9.00 | 157.49 | 139.77 | 12.68 |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PBIDT | 1.95 | 4.20 | -53.57 | 1.95 | 4.20 | -53.57 | 11.04 | 6.30 | 75.24 |
| Interest | 0.01 | 0.02 | -50.00 | 0.01 | 0.02 | -50.00 | 0.08 | 0.08 | 0.00 |
| PBDT | 1.94 | 4.18 | -53.59 | 1.94 | 4.18 | -53.59 | 10.96 | 6.22 | 76.21 |
| Depreciation | 0.37 | 0.29 | 27.59 | 0.37 | 0.29 | 27.59 | 1.42 | 0.98 | 44.90 |
| PBT | 1.57 | 3.89 | -59.64 | 1.57 | 3.89 | -59.64 | 9.54 | 5.24 | 82.06 |
| TAX | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.49 | 1.16 | 114.66 |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.08 | -0.01 | 700.00 |
| PAT | 1.57 | 3.89 | -59.64 | 1.57 | 3.89 | -59.64 | 7.05 | 4.08 | 72.79 |
| Equity | 44.81 | 44.81 | 0.00 | 44.81 | 44.81 | 0.00 | 44.81 | 44.81 | 0.00 |
| PBIDTM(%) | 5.90 | 11.56 | -48.98 | 5.90 | 11.56 | -48.98 | 7.01 | 4.51 | 55.52 |
Read More
Aug
4
2026
Posted on Aug 4th 2026
Dr Agarwals Eye Hosp - Quaterly Results
The June 2026 quarter revenue stood at Rs. 1429.70 millions, up 22.28% as compared to Rs. 1169.20 millions during the corresponding quarter last year.A good growth in profit of 35.46% reported to Rs. 233.80 millions over Rs. 172.60 millions of corresponding previous quarter.The company reported a good operating profit of 452.20 millions compared to 379.30 millions of corresponding previous quarter.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 1429.70 | 1169.20 | 22.28 | 1429.70 | 1169.20 | 22.28 | 4708.70 | 3971.50 | 18.56 |
| Other Income | 19.60 | 8.00 | 145.00 | 19.60 | 8.00 | 145.00 | 58.20 | 50.90 | 14.34 |
| PBIDT | 452.20 | 379.30 | 19.22 | 452.20 | 379.30 | 19.22 | 1511.30 | 1235.90 | 22.28 |
| Interest | 27.70 | 41.60 | -33.41 | 27.70 | 41.60 | -33.41 | 118.80 | 134.40 | -11.61 |
| PBDT | 424.50 | 337.70 | 25.70 | 424.50 | 337.70 | 25.70 | 1392.50 | 1101.50 | 26.42 |
| Depreciation | 114.90 | 105.80 | 8.60 | 114.90 | 105.80 | 8.60 | 456.40 | 394.50 | 15.69 |
| PBT | 309.60 | 231.90 | 33.51 | 309.60 | 231.90 | 33.51 | 936.10 | 707.00 | 32.40 |
| TAX | 75.80 | 59.30 | 27.82 | 75.80 | 59.30 | 27.82 | 235.10 | 160.50 | 46.48 |
| Deferred Tax | -0.90 | 0.10 | -1000.00 | -0.90 | 0.10 | -1000.00 | 0.40 | 2.40 | -83.33 |
| PAT | 233.80 | 172.60 | 35.46 | 233.80 | 172.60 | 35.46 | 701.00 | 546.50 | 28.27 |
| Equity | 48.30 | 47.00 | 2.77 | 48.30 | 47.00 | 2.77 | 48.30 | 47.00 | 2.77 |
| PBIDTM(%) | 31.63 | 32.44 | -2.50 | 31.63 | 32.44 | -2.50 | 32.10 | 31.12 | 3.14 |
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Brooks Laboratories Ltd. is ₹61.00 as of 2026-08-04.
The market capitalisation of Brooks Laboratories Ltd. is ₹185.43 as of 2026-08-03.
The 1-year return of Brooks Laboratories Ltd. is -96.04% as of 2026-08-04.
The P/E ratio of Brooks Laboratories Ltd. is 0.00 as of 2026-08-04.
The 52-week high and low of Brooks Laboratories Ltd. are ₹164.02 and ₹36.30, respectively, as of 2026-08-04.
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
